Company intelligence / Profile preview
Remedium Bio
Needham, Massachusetts, United Statesremedium-bio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Remedium Bio’s lead candidate RMD1202—a single-injection GLP‑1 RA gene therapy for type 2 diabetes and obesity—has demonstrated preclinical proof-of-concept. The company’s Prometheus™ platform enables durable protein expression with post-treatment dose adjustment. Additional programs include a disease-modifying treatment for osteoarthritis (RMD1101) and other regenerative therapeutics targeting major chronic conditions. No clinical trial results have been published yet; the company remains at the preclinical stage.
- Therapeutic areas
- EndocrinologyRheumatologyNeurology
- Modalities
- Gene therapy (adjustable-dose platform)Protein/peptide delivery via gene therapy (e.g., GLP‑1 RA)Antibody delivery via gene therapyGrowth factor restoration
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
Request access →03
Partnerships
Wharton Alumni Angels (investor partnership)Ulu Ventures investment partnership to accelerate development of lead asset RMD1202 to first-in-human studies.
Beyond the preview
Go deeper on Remedium Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Remedium Bio.